First, the percentages of CD20+ (IM-TLSs with GCs: p<0.0001, CT-TLSs with GCs: p<0.0001, total TLSs with GCs: p<0.0001; Figure 5A) and CD23+ GC B cells (p<0.0001, p<0.0001, p<0.0001, Figure 5B) and DC-LAMP+ mature DCs (p=0.0003, p<0.0001, p=0.0084, Figure 5C) were significantly greater in TLSs with GCs, including IM-TLSs with GCs, CT-TLSs with GCs and total TLSs with GCs, compared with the corresponding tumour TLSs without GCs. The gene discussed is FCER2; the disease is neoplasm.